{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:25:12Z","timestamp":1777134312431,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00765-3","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T07:12:51Z","timestamp":1748848371000},"page":"1475-1493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical, Humanistic, and Economic Value of \u2018Good ON-Time\u2019 in Advanced Parkinson\u2019s Disease: A Multinational Real-World Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9772-7569","authenticated-orcid":false,"given":"Joohi","family":"Jimenez-Shahed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-9223","authenticated-orcid":false,"given":"Irene A.","family":"Malaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-1179","authenticated-orcid":false,"given":"Ashwini","family":"Parab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1467-4666","authenticated-orcid":false,"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-4343","authenticated-orcid":false,"given":"Prasanna L.","family":"Kandukuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Zamudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"765_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/ijms18030551","volume":"18","author":"R Cacabelos","year":"2017","unstructured":"Cacabelos R. Parkinson\u2019s disease: from pathogenesis to pharmacogenomics. Int J Mol Sci. 2017;18:551.","journal-title":"Int J Mol Sci"},{"key":"765_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/WCO.0000000000000118","volume":"27","author":"JC Giugni","year":"2014","unstructured":"Giugni JC, Okun MS. Treatment of advanced Parkinson\u2019s disease. Curr Opin Neurol. 2014;27:450\u201360.","journal-title":"Curr Opin Neurol"},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.nrl.2013.05.002","volume":"28","author":"J Kulisevsky","year":"2013","unstructured":"Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson\u2019s disease: clinical characteristics and treatment. Part II. Neurologia. 2013;28:558\u201383.","journal-title":"Neurologia"},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol. 2006;2:382\u201392.","journal-title":"Nat Clin Pract Neurol"},{"key":"765_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19:50.","journal-title":"BMC Neurol"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00415-022-11546-5","volume":"270","author":"P Martinez-Martin","year":"2023","unstructured":"Martinez-Martin P, Skorvanek M, Henriksen T, Lindvall S, Domingos J, Alobaidi A, et al. Impact of advanced Parkinson\u2019s disease on caregivers: an international real-world study. J Neurol. 2023;270:2162\u201373.","journal-title":"J Neurol"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Azulay J-P, Odin P, Lindvall S, Domingos J, Alobaidi A, et al. Economic burden of Parkinson\u2019s disease: a multinational, real-world, cost-of-illness study drugs. Real World Outcomes. 2024;11:1\u201311.","journal-title":"Real World Outcomes"},{"key":"765_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-020-0117-1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson\u2019s disease in the US. npj Parkinsons Dis. 2020;6:1\u20139.","journal-title":"npj Parkinsons Dis."},{"key":"765_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.28265","volume":"36","author":"N Dahodwala","year":"2021","unstructured":"Dahodwala N, Li P, Jahnke J, Ladage VP, Pettit AR, Kandukuri PL, et al. Burden of Parkinson\u2019s disease by severity: health care costs in the US medicare population. Mov Disord. 2021;36:133\u201342.","journal-title":"Mov Disord"},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/ane.13502","volume":"144","author":"F Hjalte","year":"2021","unstructured":"Hjalte F, Norlin JM, Kellerborg K, Odin P. Parkinson\u2019s disease in Sweden-resource use and costs by severity. Acta Neurol Scand. 2021;144:592\u20139.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"765_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-022-02560-1","volume":"22","author":"IA Malaty","year":"2022","unstructured":"Malaty IA, Martinez-Martin P, Chaudhuri KR, et al. Does the 5-2-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. 2022;22(1):35.","journal-title":"BMC Neurol"},{"issue":"12","key":"765_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373.","journal-title":"Curr Med Res Opin"},{"key":"765_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/13696998.2021.1913009","volume":"24","author":"A Thach","year":"2021","unstructured":"Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A. Real-world assessment of \u201cOFF\u201d episode-related healthcare resource utilization among patients with Parkinson\u2019s disease in the United States. J Med Econ. 2021;24:540\u20139.","journal-title":"J Med Econ"},{"key":"765_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12883-021-02074-2","volume":"21","author":"A Thach","year":"2021","unstructured":"Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A. Real-world assessment of the impact of \u201cOFF\u201d episodes on health-related quality of life among patients with Parkinson\u2019s disease in the United States. BMC Neurol. 2021;21:46.","journal-title":"BMC Neurol"},{"key":"765_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.20248","volume":"19","author":"RA Hauser","year":"2004","unstructured":"Hauser RA, Deckers F, Lehert P. Parkinson\u2019s disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19:1409\u201313.","journal-title":"Mov Disord"},{"key":"765_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/02692163231214408","volume":"38","author":"M Garon","year":"2024","unstructured":"Garon M, Weck C, Rosqvist K, et al. A systematic practice review: providing palliative care for people with Parkinson\u2019s disease and their caregivers. Palliat Med. 2024;38:57\u201368.","journal-title":"Palliat Med"},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141\u20139.","journal-title":"Lancet Neurol"},{"key":"765_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301:63\u201373.","journal-title":"JAMA"},{"key":"765_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749\u201359.","journal-title":"Lancet Neurol"},{"key":"765_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, et al. Safety and efficacy of continuous subcutaneous foslevodopa\u2013foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21:1099\u2013109.","journal-title":"Lancet Neurol"},{"key":"765_CR21","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther. 2023;12:1937\u201358.","journal-title":"Neurol Ther"},{"key":"765_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40120-022-00332-0","volume":"11","author":"R Pahwa","year":"2022","unstructured":"Pahwa R, Aldred J, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, et al. Patterns of daily motor-symptom control with carbidopa\/levodopa enteral suspension versus oral carbidopa\/levodopa therapy in advanced Parkinson\u2019s disease: clinical trial post hoc analyses. Neurol Ther. 2022;11:711\u201323.","journal-title":"Neurol Ther"},{"key":"765_CR23","doi-asserted-by":"crossref","unstructured":"Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-shahed J, Metz S, et al. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson\u2019s disease continuum: revelations from the MANAGE-PD validation cohort. Parkinsonism and Related Disorders [Internet]. 2023 [cited 2024 Jul 18];116. https:\/\/www.prd-journal.com\/article\/S1353-8020(23)00237-7\/fulltext.","DOI":"10.1016\/j.parkreldis.2023.105514"},{"key":"765_CR24","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24:3063\u201372.","journal-title":"Curr Med Res Opin"},{"key":"765_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6: e010352.","journal-title":"BMJ Open"},{"key":"765_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. DMSO. 2016;9:371\u201380.","journal-title":"DMSO"},{"key":"765_CR27","unstructured":"Code of Conduct\/AER | EPHMRA [Internet]. [cited 2024 Jul 19]. https:\/\/www.ephmra.org\/code-conduct-aer."},{"key":"765_CR28","unstructured":"hitech_act_excerpt_from_arra_with_index.pdf [Internet]. [cited 2024 Jul 19]. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf."},{"key":"765_CR29","unstructured":"privacysummary.pdf [Internet]. [cited 2024 Jul 19]. https:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf."},{"key":"765_CR30","unstructured":"Procedure Price Lookup for Outpatient Services|Medicare.gov [Internet]. [cited 2024 Jul 18]. https:\/\/www.medicare.gov\/procedure-price-lookup\/."},{"key":"765_CR31","unstructured":"OpenDataNI. Health Trust Reference Costs 2017\u201318 [Internet]. 2019 [cited 2024 Jul 18] . https:\/\/www.data.gov.uk\/dataset\/71367291-5636-460f-a8fe-374780a16a8e\/health-trust-reference-costs-2017-18"},{"key":"765_CR32","unstructured":"Welcome to Ministry of Health, Labour and Welfare [Internet]. [cited 2024 Jul 18]. https:\/\/www.mhlw.go.jp\/english\/index.html."},{"key":"765_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"765_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2010.08.012","volume":"17","author":"S-E Soh","year":"2011","unstructured":"Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord. 2011;17:1\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"765_CR35","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.28047","volume":"35","author":"KR Chaudhuri","year":"2020","unstructured":"Chaudhuri KR, Jenner P, Antonini A. Dyskinesia matters: but not as much as it used to. Mov Disord. 2020;35:900\u20131.","journal-title":"Mov Disord"},{"key":"765_CR36","first-page":"9917539","volume":"2021","author":"Y Hayashi","year":"2021","unstructured":"Hayashi Y, Nakagawa R, Ishido M, Yoshinaga Y, Watanabe J, Kurihara K, et al. Off time independently affects quality of life in advanced Parkinson\u2019s disease (APD) patients but not in non-APD patients: results from the self-reported Japanese Quality-of-Life Survey of Parkinson\u2019s Disease (JAQPAD) Study. Parkinsons Dis. 2021;2021:9917539.","journal-title":"Parkinsons Dis"},{"key":"765_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3233\/JPD-212874","volume":"12","author":"O Okunoye","year":"2022","unstructured":"Okunoye O, Horsfall L, Marston L, Walters K, Schrag A. Rate of hospitalizations and underlying reasons among people with Parkinson\u2019s disease\u2014population-based cohort study in UK primary care. J Parkinsons Dis. 2022;12:411\u201320.","journal-title":"J Parkinsons Dis"},{"key":"765_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1445-5994.2006.01123.x","volume":"36","author":"JA Temlett","year":"2006","unstructured":"Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson\u2019s disease. Intern Med J. 2006;36:524\u20136.","journal-title":"Intern Med J"},{"key":"765_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajem.2023.10.017","volume":"75","author":"H Al-Hakeem","year":"2024","unstructured":"Al-Hakeem H, Zhang Z, DeMarco EC, Bitter CC, Hinyard L. Emergency department visits in Parkinson\u2019s disease: the impact of comorbid conditions. Am J Emerg Med. 2024;75:7\u201313.","journal-title":"Am J Emerg Med"},{"key":"765_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-021-00313-9","volume":"11","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P, Henriksen T, Soileau MJ, Rodriguez-Cruz R, et al. Psychometric properties of clinical indicators for identification and management of advanced Parkinson\u2019s disease: real-world evidence from G7 countries. Neurol Ther. 2022;11:303\u201318.","journal-title":"Neurol Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00765-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:17:44Z","timestamp":1757179064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00765-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00765-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joohi Jimenez-Shahed has received consulting fees from Medtronic, Abbvie, Bracket, AlphaOmega, Teva, Praxis, RegenXBio, Kyowa Kirin, Amneal, and TreeFrog. She has received research funding from Annovis and Sage. She serves on the data safety monitoring board for BlueRock Therapeutics and Emalex and on an advisory board for PhotoPharmics. Aristide Merola has received grant support from the NIH (KL2 TR001426). He has received speaker honoraria or advisory board honoraria from CSL Behring, AbbVie, Abbott, Medtronic, Theravance, and Cynapsus Therapeutics. He has received grant support from Lundbeck and AbbVie. Irene\u00a0A. Malaty has participated in research funded by AbbVie, Emalex, Praxis, Neuroderm, Prilenia, Revance, and Sage but has no owner interest in any pharmaceutical company. She has received consulting fees from Abbvie, travel compensation or honoraria from Cleveland Clinic, Parkinson Foundation, Tourette Association, Medscape, and royalties from Robert Rose Publishers. Jean-Philippe Azulay has received compensation for consultancy and speaker-related activities from UCB, AbbVie, Kyowa Kirin, Zambon, Roche HAC Pharma, and Allergan. Alexander Gillespie is an employee of Adelphi Real World, a consulting company that was hired by AbbVie Inc., to perform analyses on the Adelphi Disease Specific Programme database. Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, and Roche. He receives research support from Chiesi Pharmaceuticals, Lundbeck, Bial, Horizon2020 Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, and Cariparo Foundation. He serves as consultant for Boehringer\u2013Ingelheim for legal cases on pathological gambling. Aditi Kharat, Lakshmi P. Kandukuri, Ali Alobaidi, Pavnit Kukreja, Jorge Zamudio, Ashwini Parab, and Connie H. Yan are employees of AbbVie and may own stocks\/shares in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such it does not require ethics committee approval. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 and Health Information Technology for Economic and Clinical Health Act legislation. All data were fully de-identified prior to receipt by Adelphi Real World. The respondents provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}